Targets › CYP24A1
1 program from 1 company in 1 trial: 1 Phase 2; Metabolic and endocrine; next expected readout Dec 2027.
A cytochrome P450 monooxygenase with a key role in vitamin D catabolism and calcium homeostasis. Via C24- and C23-oxidation pathways, catalyzes the inactivation of both the vitamin D precursor calcidiol (25-hydroxyvitamin D(3)) and the active hormone calcitriol (1-alpha,25-dihydroxyvitamin D(3)). (UniProt, Q07973)
Open in Phaseline: the race on CYP24A1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Children's Hospital of Philadelphia | Rifampin Bacterial DNA-directed RNA polymerase inhibitor | CYP24A1 | Phase 2 | Idiopathic Infantile Hypercalcaemia - Severe Form | Dec 2027 |
Idiopathic Infantile Hypercalcaemia - Severe Form (1)
small molecule (1)
Children's Hospital of Philadelphia (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.